Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
To assess the anti-tumor activity and safety of Tenalisib in patients with relapsed/refractory indolent Non-Hodgkin's Lymphoma (iNHL),
Non Hodgkin Lymphoma
DRUG: Tenalisib,
Objective Response Rate (ORR), ORR is defined as sum of CR and PR rates and will be assessed according to the Lugano Classification for initial evaluation, staging, and response assessment of Non-Hodgkin lymphoma. (Cheson-2014), 7 months|Complete Response Rate, CR rate will be assessed according to the Lugano Classification for initial evaluation, staging, and response assessment of non-Hodgkin lymphoma., 7 months|Progression Free Survival (PFS), PFS is defined as the time of the first dose of Tenalisib to disease progression or death., From date of first dose of tenalisib until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 7 months|Duration of Response (DoR), DoR is measured from the initial response to disease progression or death, 7 months
Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v4.0, Safety and tolerability of Tenalisib, 8 months
To assess the anti-tumor activity and safety of Tenalisib in patients with relapsed/refractory indolent Non-Hodgkin's Lymphoma (iNHL),